REG - ConvaTec Group PLC - AGM Result of Meeting

ConvaTecAnnouncement

10/05/2018 16:00

2018-05-10T14:57:25.532Zreuters.comtag:reuters.com,2018-05-10:newsml_RSJ7191Na:13TXT
This file is provided for EAP sample purposes only; it's structure and detail are subject to change, and should not be used as a definitive reference for actual development and processing.2018-05-10T14:57:25.532Z2018-05-10T14:57:25.532Z____UCDP:parsn_lse_10.54.4.69_1.2.37235:2019-06-10T14:57:25.532Z3RSJ7191NaREG - ConvaTec Group PLC  - AGM Result of MeetingHealthcare (TRBC level 1)Pharmaceuticals & Medical Research (TRBC level 2)LEGACY: Pharmaceuticals (TRBC level 3)LEGACY: Generic & Specialty Pharmaceuticals (TRBC)Proprietary & Advanced Pharmaceuticals (TRBC level 5)Pharmaceuticals (TRBC level 4)Western EuropeUnited KingdomEuropeSuggested SourcesNews AnnouncementsRegulatory Corporate News AnnouncementsCompany NewsEurope daily earnings hits & missesConvaTec Group PLC








RNS Number : 7191N
ConvaTec Group PLC
10 May 2018
 

 
Result of Meeting
 
 
CONVATEC GROUP PLC - AGM
10 MAY 2018 - POLL RESULT
 
ConvaTec Group Plc ("ConvaTec"), a leading global medical products and technologies company, held its annual general meeting today.  The results of the poll held in relation to the resolutions proposed at the meeting are set out below.
 








For (see note 2)


Against (see note 2)


Number of votes Withheld (see note 3)


Total Capital Instructed




Resolution


No of shares


%


No of Shares


%




1


Receive Annual Report and Accounts


1,490,995,091


100.00


2,052


0.00


1,490,997,143


76.39%




2


Approve the Directors' Remuneration Report


1,457,090,861


98.33


24,766,857


1.67


1,481,857,718


75.92%




3


Declare Final Dividend


1,490,997,143


100.00


0


0.00


1,490,997,143


76.39%




4


Re-elect Sir Christopher Gent as a Director


1,483,108,674


99.47


7,885,399


0.53


1,490,994,073


76.39%




5


Re-elect Paul Moraviec as a Director


1,488,939,928


99.86


2,054,145


0.14


1,490,994,073


76.39%




6


Elect Frank Schulkes as a Director


1,481,688,827


99.38


9,305,246


0.62


1,490,994,073


76.39%




7


Re-elect Steve Holliday as a Director


1,482,717,535


99.44


8,277,540


0.56


1,490,995,075


76.39%




8


Re-elect Jesper Ovesen as a Director


1,476,891,196


99.05


14,102,877


0.95


1,490,994,073


76.39%




9


Re-elect Rick Anderson as a Director


1,488,985,560


99.87


2,009,487


0.13


1,490,995,047


76.39%




10


Re-elect Kasim Kutay as a Director


1,488,564,111


99.84


2,429,436


0.16


1,490,993,547


76.39%




11


Elect Ros Rivaz as a Director


1,486,522,754


99.70


4,471,319


0.30


1,490,994,073


76.39%




12


Elect Regina Benjamin as a Director


1,488,488,383


99.83


2,506,166


0.17


1,490,994,549


76.39%




13


Elect Margaret Ewing as a Director


1,488,980,460


99.86


2,014,587


0.14


1,490,995,047


76.39%




14


Re-appoint Deloitte LLP as auditors


1,490,989,671


100.00


6,418


0.00


1,490,996,089


76.39%




15


Authorise the Directors to agree the auditors' remuneration


1,490,994,110


100.00


3,033


0.00


1,490,997,143


76.39%




16


Authorise allotment of shares


1,479,661,716


99.25


11,131,674


0.75


1,490,793,390


76.38%




17


Disapply pre-emption rights*


1,490,781,972


99.99


213,817


0.01


1,490,995,789


76.39%




18


Disapply pre-emption rights in connection with an acquisition or specified capital investment*


1,428,938,102


95.84


62,052,586


4.16


1,490,990,688


76.39%




19


Authorise purchase of own shares*


1,485,284,913


99.75


3,698,352


0.25


1,488,983,265


76.29%




20


Authorise political donations and political expenditure


1,485,209,550


99.91


1,303,630


0.09


1,486,513,180


76.16%




21


Call general meetings on 14 days' notice*


1,442,987,025


97.07


43,526,671


2.93


1,486,513,696


76.16%




 
*Special Resolution
 




NOTES:
 
1.   All resolutions were passed.
2.   Votes "For" and "Against" are expressed as a percentage of votes received.
3.   A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
4.   Total number of shares in issue at 6.30pm on 8 May 2018 was 1,951,850,599 shares.  Up to 76.39% of voting capital was instructed.
 
 
 
 
 
About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and has leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.  www.convatecgroup.com
 
 
This information is provided by RNS
The company news service from the London Stock Exchange
 
Enquiries
 
Analysts and Investors
 
John Crosse, VP Investor Relations                                             +44 (0)7500 141 435
Kirsty Law, Director Investor Relations                                         +44 (0)7470 909 582
investorrelations@convatec.com
 
Media
 
Bobby Leach, VP Group Corporate Affairs                                    +44 (0)7770 842 226
Finsbury                                                                                    +44 (0)207 251 3801



ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
# # #
END
 



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGEALSEFSSPEFF